Investigating Weak Polypeptide‐Cyclodextrin Interactions in Biologic Formulation Development Using Affinity Capillary Electrophoresis and Flow‐Induced Dispersion Analysis
ELECTROPHORESIS · 2025
DOI: 10.1002/elps.70000 ↗Kurz gefasst
Fachartikel in der Zeitschrift ELECTROPHORESIS, 2025. Verfasst von Yunxiao Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Drug Product Development, Bristol-Myers Squibb, New Brunswick, New Jersey, USA. Hauptthemen laut MEDLINE: beta-Cyclodextrins, Relaxin, Cyclodextrins, Peptides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Understanding protein–excipient interactions is vital for biopharmaceutical formulation, as they influence stability and pharmacokinetics (PK). Cyclodextrins (CDs) are widely used excipients that enhance solubility and stability, but their weak interactions with polypeptides remain poorly characterized. Relaxin (RLX), a potent anti‐heart failure polypeptide, was selected due to its PK relevance and in vivo interaction with human serum albumin (HSA). Given RLX's poor solubility, CDs were identified as the most effective solubilizers. However, traditional affinity assays lack the sensitivity to detect weak CD‐polypeptide interactions. To overcome this limitation, we employed affinity capillary electrophoresis and flow‐induced dispersion analysis (FIDA) to assess RLX's binding with hydroxypropyl‐β‐cyclodextrin (HP‐β‐CD) and sulfobutylether‐β‐cyclodextrin (SBE‐β‐CD). Our results showed a higher affinity for SBE‐β‐CD than HP‐β‐CD, though both interactions were significantly weaker than RLX's binding to HSA. These findings provide key insights into weak CD‐polypeptide interactions, supporting SBE‐β‐CD as an excipient to improve solubility without compromising PK performance. Additionally, the effectiveness of these rapid, nonconventional analytical methods was validated through in vivo PK studies in a cynomolgus monkey model, highlighting their value in excipient–protein binding research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Product Development, Bristol-Myers Squibb, New Brunswick, New Jersey, USA.
Zitieren
APA
Zhu, Y., Thati, S., Mccallum, M., Mantri, R., Ying, W., Mathias, N., Bolgar, M., & Lan, W. (2025). Investigating Weak Polypeptide‐Cyclodextrin Interactions in Biologic Formulation Development Using Affinity Capillary Electrophoresis and Flow‐Induced Dispersion Analysis. ELECTROPHORESIS. https://doi.org/10.1002/elps.70000
Vancouver
Zhu Y, Thati S, Mccallum M, Mantri R, Ying W, Mathias N, et al. Investigating Weak Polypeptide‐Cyclodextrin Interactions in Biologic Formulation Development Using Affinity Capillary Electrophoresis and Flow‐Induced Dispersion Analysis. ELECTROPHORESIS. 2025. doi:10.1002/elps.70000
BibTeX
@article{Zhu2025,
author = {Zhu, Yunxiao and Thati, Sharadvi and Mccallum, Megan and Mantri, Rao and Ying, William and Mathias, Neil and Bolgar, Mark and Lan, Wenkui},
title = {Investigating Weak Polypeptide‐Cyclodextrin Interactions in Biologic Formulation Development Using Affinity Capillary Electrophoresis and Flow‐Induced Dispersion Analysis},
journal = {ELECTROPHORESIS},
year = {2025},
doi = {10.1002/elps.70000}
}
EUVIMED